Grail released updated PATHFINDER 2 data showing improved positive predictive value (PPV) and sensitivity for its multi‑cancer blood test, Galleri, strengthening the company’s case ahead of regulatory filings. In a cohort of nearly 36,000 adults, the test detected 40.4% of cancers with a higher proportion of early‑stage detections and about 62% of positive tests corresponding to true cancer cases in longer‑term follow‑up. Researchers flagged that many detected cancers are types not covered by current screening guidelines, such as pancreatic and liver cancers, which complicates downstream diagnostic pathways. Experts noted improvements in PPV versus earlier studies but raised questions about clinical workflows, overdiagnosis, and confirmatory testing burdens in real‑world settings. Grail’s results could influence payer and regulator assessments of screening utility and cost‑effectiveness as the company advances toward broader deployment.